206 related articles for article (PubMed ID: 17439838)
1. Immunohistochemical evaluation of necrotic malignant melanomas.
Nonaka D; Laser J; Tucker R; Melamed J
Am J Clin Pathol; 2007 May; 127(5):787-91. PubMed ID: 17439838
[TBL] [Abstract][Full Text] [Related]
2. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations.
Sheffield MV; Yee H; Dorvault CC; Weilbaecher KN; Eltoum IA; Siegal GP; Fisher DE; Chhieng DC
Am J Clin Pathol; 2002 Dec; 118(6):930-6. PubMed ID: 12472287
[TBL] [Abstract][Full Text] [Related]
3. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.
Miettinen M; Fernandez M; Franssila K; Gatalica Z; Lasota J; Sarlomo-Rikala M
Am J Surg Pathol; 2001 Feb; 25(2):205-11. PubMed ID: 11176069
[TBL] [Abstract][Full Text] [Related]
4. [Reactivity of five different antibodies with benign and malignant melanocytic lesions].
Plótár V; Szentirmay Z; Orosz Z
Magy Onkol; 2008 Dec; 52(4):363-73. PubMed ID: 19068464
[TBL] [Abstract][Full Text] [Related]
5. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma.
Gleason BC; Nascimento AF
Am J Dermatopathol; 2007 Feb; 29(1):22-7. PubMed ID: 17284958
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical identification of canine melanocytic neoplasms with antibodies to melanocytic antigen PNL2 and tyrosinase: comparison with Melan A.
Ramos-Vara JA; Miller MA
Vet Pathol; 2011 Mar; 48(2):443-50. PubMed ID: 20858741
[TBL] [Abstract][Full Text] [Related]
7. S100, HMB-45, and Melan-A negative primary melanoma.
Shinohara MM; Deubner H; Argenyi ZB
Dermatol Online J; 2009 Sep; 15(9):7. PubMed ID: 19930994
[TBL] [Abstract][Full Text] [Related]
8. HMB-45 may be a more sensitive maker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas.
Yu CH; Chen HH; Liu CM; Jeng YM; Wang JT; Wang YP; Liu BY; Sun A; Chiang CP
J Oral Pathol Med; 2005 Oct; 34(9):540-5. PubMed ID: 16138892
[TBL] [Abstract][Full Text] [Related]
9. [Distribution of melanoma-associated antigens (HMB 45 and S 100) in benign and malignant melanocytic tumors of the conjunctiva].
Steuhl KP; Rohrbach JM; Knorr M
Klin Monbl Augenheilkd; 1991 Sep; 199(3):187-91. PubMed ID: 1753671
[TBL] [Abstract][Full Text] [Related]
10. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections.
Kaufmann O; Koch S; Burghardt J; Audring H; Dietel M
Mod Pathol; 1998 Aug; 11(8):740-6. PubMed ID: 9720502
[TBL] [Abstract][Full Text] [Related]
11. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.
Xu X; Chu AY; Pasha TL; Elder DE; Zhang PJ
Am J Surg Pathol; 2002 Jan; 26(1):82-7. PubMed ID: 11756773
[TBL] [Abstract][Full Text] [Related]
12. Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa.
Prasad ML; Jungbluth AA; Iversen K; Huvos AG; Busam KJ
Am J Surg Pathol; 2001 Jun; 25(6):782-7. PubMed ID: 11395556
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical characteristics of melanoma.
Ohsie SJ; Sarantopoulos GP; Cochran AJ; Binder SW
J Cutan Pathol; 2008 May; 35(5):433-44. PubMed ID: 18399807
[TBL] [Abstract][Full Text] [Related]
14. PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck.
Morris LG; Wen YH; Nonaka D; DeLacure MD; Kutler DI; Huan Y; Wang BY
Head Neck; 2008 Jun; 30(6):771-5. PubMed ID: 18228523
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotypic differences between uveal and cutaneous melanomas.
Iwamoto S; Burrows RC; Kalina RE; George D; Boehm M; Bothwell MA; Schmidt R
Arch Ophthalmol; 2002 Apr; 120(4):466-70. PubMed ID: 11934320
[TBL] [Abstract][Full Text] [Related]
16. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases.
Hisaoka M; Ishida T; Kuo TT; Matsuyama A; Imamura T; Nishida K; Kuroda H; Inayama Y; Oshiro H; Kobayashi H; Nakajima T; Fukuda T; Ae K; Hashimoto H
Am J Surg Pathol; 2008 Mar; 32(3):452-60. PubMed ID: 18300804
[TBL] [Abstract][Full Text] [Related]
17. Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens.
Dorvault CC; Weilbaecher KN; Yee H; Fisher DE; Chiriboga LA; Xu Y; Chhieng DC
Cancer; 2001 Oct; 93(5):337-43. PubMed ID: 11668469
[TBL] [Abstract][Full Text] [Related]
18. S-100 protein-negative malignant melanoma: fact or fiction? A light-microscopic and immunohistochemical study.
Argenyi ZB; Cain C; Bromley C; Nguyen AV; Abraham AA; Kerschmann R; LeBoit PE
Am J Dermatopathol; 1994 Jun; 16(3):233-40. PubMed ID: 7943629
[TBL] [Abstract][Full Text] [Related]
19. Sclerosing PEComa: clinicopathologic analysis of a distinctive variant with a predilection for the retroperitoneum.
Hornick JL; Fletcher CD
Am J Surg Pathol; 2008 Apr; 32(4):493-501. PubMed ID: 18223480
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical study of microphthalmia transcription factor and tyrosinase in angiomyolipoma of the kidney, renal cell carcinoma, and renal and retroperitoneal sarcomas: comparative evaluation with traditional diagnostic markers.
Zavala-Pompa A; Folpe AL; Jimenez RE; Lim SD; Cohen C; Eble JN; Amin MB
Am J Surg Pathol; 2001 Jan; 25(1):65-70. PubMed ID: 11145253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]